TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15319314

Group type: EXPERIMENTAL
Intervention: Adolescents with bilateral periventricular leukomalacia (PVL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched peers (term-born adolescents and former preterms with normal MRI scan)
Number of subjects: 0
Study: 11833996

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia with Mg2+ (BC‐Mg2+, n = 200)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Blood cardioplegia without Mg2+ (BC, n = 200)
Number of subjects: 400
Study: 10891631

Group type: EXPERIMENTAL
Intervention: Clients enrolled in Project MATCH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clients not entered into the study
Number of subjects: 0
Study: 8703460

Group type: EXPERIMENTAL
Intervention: Autologous blood reinfusion
Number of subjects: 20
Study: 1551535

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg once daily before breakfast
Number of subjects: 240

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 4089577

Group type: EXPERIMENTAL
Intervention: Highly purified duck embryo rabies vaccine (PDEV) administered according to WHO post-exposure schedule (6 injections on days 0, 3, 7, 14, 28, and 90)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly purified duck embryo rabies vaccine (PDEV)
Number of subjects: 0
Study: 31694682

Group type: EXPERIMENTAL
Intervention: Recruitment efforts using community ads and direct phone calls by study staff
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Qualitative evaluations of recruitment barriers
Number of subjects: 140
Study: 28318872

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone injection into the pterygomandibular space
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 31
Study: 26216071

Group type: EXPERIMENTAL
Intervention: Higher dose gefitinib (500 mg/d; H group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard dose gefitinib (250 mg/d; S group)
Number of subjects: 100
Study: 23336248

Group type: EXPERIMENTAL
Intervention: Opicapone 5, 10, 20 or 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21315203

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 19619697

Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG)
Number of subjects: 170
Study: 16987384

Group type: EXPERIMENTAL
Intervention: Quinidine plus verapamil (Q+V) 480/240 mg/day
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Quinidine plus verapamil (Q+V) 320/160 mg/day
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/day
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1033

Group type: EXPERIMENTAL
Intervention: Both antiarrhythmics (Q+V and sotalol)
Number of subjects: 1033
Study: 12767414

Group type: EXPERIMENTAL
Intervention: Ginkgo (240 mg/d or 160 mg/d)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo (0 mg/d)
Number of subjects: 214
Study: 11074682

Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 1435

Group type: COMPARATOR
Intervention: 2-3 days of bed rest
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Advice to stay active
Number of subjects: 1435
Study: 9159689

Group type: EXPERIMENTAL
Intervention: High-frequency capsulotomy (n = 27)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Continuous curvilinear capsulorhexis (CCC) (n = 26)
Number of subjects: 53
Study: 8381800

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3120989

Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin (1 mg daily for mean 20 days)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Full dose oral anticoagulation
Number of subjects: 104

Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Fixed minidose warfarin
Number of subjects: 104
Study: 28500434

Group type: EXPERIMENTAL
Intervention: Coping Power (group) program
Number of subjects: 114

Group type: COMPARATOR
Intervention: Individualized parent-child treatment
Number of subjects: 114
Study: 26599569

Group type: EXPERIMENTAL
Intervention: Intramuscular benzathine benzylpenicillin (BPG)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Twice daily co‐trimoxazole (SXT) for 3 days (4 mg/kg trimethoprim plus 20 mg/kg sulfamethoxazole per dose)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Once daily SXT for 5 days (8 mg/kg trimethoprim plus 40 mg/kg sulfamethoxazole per dose)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Pooled SXT groups
Number of subjects: 508

Group type: COMPARATOR
Intervention: BPG group
Number of subjects: 508
Study: 26631000

Group type: EXPERIMENTAL
Intervention: OB Nest intervention with 8 pre-planned office visits and 6 telephone or online nurse visits, plus home monitoring equipment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OB Nest intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care with 12 pre-planned physician or midwife office visits.
Number of subjects: 0
Study: 23394910

Group type: EXPERIMENTAL
Intervention: Herpes zoster vaccine administered by ophthalmologists
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients who declined the herpes zoster vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Reasons for declining the vaccine
Number of subjects: 100
Study: 21957237

Group type: EXPERIMENTAL
Intervention: Perceptual learning variant of the serial reaction time task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motor learning variant of the serial reaction time task
Number of subjects: 0
Study: 18453305

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2326

Group type: COMPARATOR
Intervention: Neither medication
Number of subjects: 2326
Study: 16533874

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 14662276

Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lenses
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Run-in period prior to randomized treatment-group assignment
Number of subjects: 147
Study: 11153922

Group type: EXPERIMENTAL
Intervention: Dynamic/static tests
Number of subjects: 250

Group type: COMPARATOR
Intervention: Other clinical tests (palpation, function tests)
Number of subjects: 250
Study: 9106558

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone, 10 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ethinyl estradiol, 50 microg
Number of subjects: 7
Study: 8024639

Group type: EXPERIMENTAL
Intervention: Deflazacort (6 mg/tablet)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Prednisone (5 mg/tablet)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 76

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Deflazacort and Prednisone
Number of subjects: 76
Study: 2637388

Group type: EXPERIMENTAL
Intervention: diazepam 5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: amobarbital 80 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: methylphenidate 15 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study: 1157671

Group type: EXPERIMENTAL
Intervention: Econazole administered as vaginal cream (1077 patients)
Number of subjects: 2103

Group type: EXPERIMENTAL
Intervention: Econazole administered in ovules (1026 patients)
Number of subjects: 2103
Study: 31895636

Group type: EXPERIMENTAL
Intervention: Patients not asked about financial concerns by hospital staff
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Family members not asked about financial concerns by hospital staff
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients favoring receiving information about financial services after ICU stay
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients preferring receiving information about financial services in ICU
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Family members preferring receiving information about financial services during ICU stay
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Family members preferring receiving information about financial services after ICU stay
Number of subjects: 50
Study: 27646462

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy‐Adolescent Skills Training
Number of subjects: 186

Group type: COMPARATOR
Intervention: Group counseling
Number of subjects: 186
Study: 29046273

Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 3093

Group type: COMPARATOR
Intervention: Lying down position
Number of subjects: 3093
Study: 25483416

Group type: EXPERIMENTAL
Intervention: Belinostat plus azacitidine (AZA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Azacitidine (AZA) alone
Number of subjects: 56
Study: 24739290

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Increasing volume of warm-up (4, 8, and 12 sets)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison between SS and DS
Number of subjects: 18

Group type: COMPARATOR
Intervention: No stretching treatment
Number of subjects: 18
Study: 23002121

Group type: EXPERIMENTAL
Intervention: Assisted group (experts with assistants)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (experts without assistants)
Number of subjects: 8
Study: 19717846

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180-mg loading dose, 90 mg twice daily thereafter)
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter)
Number of subjects: 18624

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study: 17697303

Group type: EXPERIMENTAL
Intervention: Norepinephrine at MAP of 65 mmHg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Norepinephrine at MAP of 85 mmHg
Number of subjects: 8
Study: 15131454

Group type: EXPERIMENTAL
Intervention: Specific stabilizing exercises for pelvic girdle pain
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 81
Study: 12658810

Group type: EXPERIMENTAL
Intervention: Clavulanate Potassium and Amoxicillin (1:7) dispersible tablets (Tested formulation, T)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Augmentin syrup (Reference formulation, R)
Number of subjects: 18
Study: 9674880

Group type: EXPERIMENTAL
Intervention: Video-based training, prompts installed in the pharmacy, group-based feedback on counseling rates
Number of subjects: 178
Study: 7488579

Group type: EXPERIMENTAL
Intervention: 78 dioptre lens
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Optic disc biometer
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison of both methods
Number of subjects: 29
Study: 2287055

Group type: EXPERIMENTAL
Intervention: S 6472 (750 mg twice daily for 5 days)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Conventional cefaclor preparation (CCL) (500 mg three times daily for 5 days)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: S 6472
Number of subjects: 280

Group type: COMPARATOR
Intervention: CCL
Number of subjects: 280
Study: 6988033

Group type: EXPERIMENTAL
Intervention: Transverse incisions
Number of subjects: 579

Group type: COMPARATOR
Intervention: Midline incisions
Number of subjects: 579
Study: 31650182

Group type: EXPERIMENTAL
Intervention: Elagolix 100 mg QD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg QD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg QD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elagolix 100 mg BID
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg BID
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg BID
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg BID plus E2/NETA 1/0.5 mg QD
Number of subjects: 100
Study: 30834932

Group type: EXPERIMENTAL
Intervention: Behavioural e‐learning intervention to support nurses in managing interruptions during medication administration
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Behavioural strategies (engagement and multitasking)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 806
Study: 28680858

Group type: EXPERIMENTAL
Intervention: Agarose bead instillation (sterile)
Number of subjects: 0

Group type: COMPARATOR
Intervention: P. aeruginosa-loaded beads
Number of subjects: 0
Study: 26799904

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Exposure Therapy (CET)
Number of subjects: 0
Study: 23944299

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation (IPPV)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 1009
Study: 22152833

Group type: EXPERIMENTAL
Intervention: Primary care sequential screening
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Primary care parallel screening
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Midwife care screening
Number of subjects: 10000
Study: 19745565

Group type: EXPERIMENTAL
Intervention: Microdose of nicardipine (100 microg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clinical dose of nicardipine (20 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In vitro metabolites of nicardipine
Number of subjects: 6
Study: 16504861

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) with freeze-dried bone allograft (FDBA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Freeze-dried bone allograft (FDBA) without PRF
Number of subjects: 9
Study: 12576412

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise (30% of maximum)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Maximal treadmill exercise
Number of subjects: 24
Study: 10686190

Group type: EXPERIMENTAL
Intervention: r-hFSH (Gonal-F)
Number of subjects: 278

Group type: COMPARATOR
Intervention: u-hFSH HP (Metrodin HP)
Number of subjects: 278
Study: 1794430

Group type: EXPERIMENTAL
Intervention: Tropicamide 1% in micro drop formulation (50 micrograms tropicamide)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tropicamide 1% in combination with phenylephrine 10%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Micro drops of tropicamide 0.5% (25 micrograms tropicamide)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard 'minim' drop size (26 microliters)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Micro drop of five microliters
Number of subjects: 60
Study: 6403956

Group type: EXPERIMENTAL
Intervention: Co-dergocrine mesylate 4.5 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31702797

Group type: EXPERIMENTAL
Intervention: NIH prevention research measuring a leading cause of death as an outcome or exposure
Number of subjects: 11082

Group type: EXPERIMENTAL
Intervention: NIH prevention research measuring a leading risk factor for death
Number of subjects: 11082

Group type: EXPERIMENTAL
Intervention: NIH prevention research measuring a leading risk factor for disability-adjusted life-years lost
Number of subjects: 11082

Group type: EXPERIMENTAL
Intervention: Involvement of randomized clinical trials in NIH prevention research
Number of subjects: 11082

Group type: EXPERIMENTAL
Intervention: Involvement of multiple leading causes or risk factors in NIH prevention research
Number of subjects: 11082

Group type: EXPERIMENTAL
Intervention: Involvement of multiple risk factors in NIH prevention research
Number of subjects: 11082
Study: 30265640

Group type: EXPERIMENTAL
Intervention: Reverse half hitch alternating-post (RHAP) knots
Number of subjects: 21

Group type: COMPARATOR
Intervention: Square knots
Number of subjects: 21
Study: 26066701

Group type: EXPERIMENTAL
Intervention: High-span APAP (range 4-15cmH2O, n=38)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Low-span APAP (range 8-12cmH2O, n=38)
Number of subjects: 76
Study: 24658985

Group type: EXPERIMENTAL
Intervention: Supine position (Group A)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Prone position (Group B)
Number of subjects: 119
Study: 22512698

Group type: EXPERIMENTAL
Intervention: 500 mg olive leaf extract tablet taken orally once daily
Number of subjects: 79

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Olive leaf extract
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intestine without olive leaf treatment
Number of subjects: 79
Study: 20220418

Group type: EXPERIMENTAL
Intervention: CT scanning
Number of subjects: 402

Group type: COMPARATOR
Intervention: Dynamic radiographs
Number of subjects: 402
Study: 18722573

Group type: EXPERIMENTAL
Intervention: Hospital clinic
Number of subjects: 76

Group type: COMPARATOR
Intervention: Private office
Number of subjects: 76
Study: 16013899

Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11910049

Group type: EXPERIMENTAL
Intervention: Lean beef enriched in oleic acid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Commercial beef
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lean beef
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low habitual beef intake
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High habitual beef intake
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Additional dietary beef
Number of subjects: 10
Study: 10493677

Group type: EXPERIMENTAL
Intervention: Bath Ankylosing Spondylitis Functional Index (BASFI)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Dougados Functional Index (DFI)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire - Specific (HAQ-S)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo control group (patients who withdrew due to flare)
Number of subjects: 79
Study: 8941114

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 24

Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 24

Group type: COMPARATOR
Intervention: CT
Number of subjects: 24
Study: 2044652

Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol) 300 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol) 600 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol) 900 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol) 150 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol) 300-900 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: K 12.148 (lifibrol)
Number of subjects: 40
Study: 6365147

Group type: EXPERIMENTAL
Intervention: PUVA and etretinate (0.75 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: PUVA and placebo
Number of subjects: 28
Study: 31353759

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) program
Number of subjects: 36
Study: 30533438

Group type: EXPERIMENTAL
Intervention: PCEA with ropivacaine
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: PCEA with levobupivacaine
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (no PCEA)
Number of subjects: 213
Study: 26976426

Group type: COMPARATOR
Intervention: Anastrozole 1 mg once per day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg with pictilisib 260 mg once per day
Number of subjects: 75
Study: 25244631

Group type: EXPERIMENTAL
Intervention: 5/0 gauge polyglactin 910 sutures
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 7/0 gauge polyglactin 910 sutures
Number of subjects: 42
Study: 24105720

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance after autologous transplantation
Number of subjects: 1159
Study: 21926153

Group type: EXPERIMENTAL
Intervention: treatment to target (TT)
Number of subjects: 493

Group type: COMPARATOR
Intervention: treatment as needed (PRN)
Number of subjects: 493
Study: 18760765

Group type: EXPERIMENTAL
Intervention: Telescope prosthesis
Number of subjects: 188

Group type: COMPARATOR
Intervention: Fellow control eyes
Number of subjects: 188
Study: 17111793

Group type: EXPERIMENTAL
Intervention: Combination of topical and systemic antibiotics
Number of subjects: 6922

Group type: EXPERIMENTAL
Intervention: Topical antimicrobials alone (or topical plus systemic versus systemic alone)
Number of subjects: 6922

Group type: COMPARATOR
Intervention: Control group (combination of topical and systemic antibiotics)
Number of subjects: 6922

Group type: COMPARATOR
Intervention: Control group (topical antimicrobials alone)
Number of subjects: 6922
Study: 14557474

Group type: EXPERIMENTAL
Intervention: Revised QUICKI at 40 mU/m(2).min (n = 30)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: QUICKI-glycerol at 40 mU/m(2).min (n = 30)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: QUICKI at 40 mU/m(2).min (n = 30)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Log HOMA at 40 mU/m(2).min (n = 30)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: All indexes at 75 mU/m(2).min (n = 118)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Revised QUICKI and QUICKI-glycerol in lean control subjects at 40 mU/m(2).min
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Revised QUICKI and QUICKI-glycerol in impaired glucose tolerance subjects
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: QUICKI and revised QUICKI
Number of subjects: 148
Study: 10814631

Group type: EXPERIMENTAL
Intervention: Cocaine (2 mg/kg intranasally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9121824

Group type: EXPERIMENTAL
Intervention: Treatment Helpfulness Questionnaire (THQ)
Number of subjects: 0
Study: 1797464

Group type: EXPERIMENTAL
Intervention: Norinyl 1+35 (35 mcg ethinyl estradiol)
Number of subjects: 1698

Group type: COMPARATOR
Intervention: Norinyl 1+50 (50 mcg mestranol)
Number of subjects: 1698

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1698